US OptionsDetailed Quotes
WVE241018C5000
- 3.30
- -0.30-8.33%
15min DelayClose Oct 4 15:59 ET
3.30High3.30Low
3.30Open3.60Pre Close5 Volume133 Open Interest5.00Strike Price1.65KTurnover427.58%IV-1.31%PremiumOct 18, 2024Expiry Date3.41Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8561Delta0.0351Gamma2.04Leverage Ratio-0.0635Theta0.0010Rho1.74Eff Leverage0.0034Vega
Wave Life Sciences Stock Discussion
In a notable transaction, GSK (LON:GSK) plc, a major player in the pharmaceutical industry, has recently increased its stake in Wave Life Sciences Ltd . (NASDAQ:WVE). The acquisition involved the purchase of 2,791,930 ordinary shares at a price of $8.00 per share, amounting to a total investment of $22.3 million.
This strategic move by GSK plc, which is known for its diverse portfolio of healthca...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Wave Life Sciences announced positive interim data from the FORWARD-53 clinical trial evaluating WVE-N531 in boys with Duchenne Muscular Dystrophy (DMD) amenable to exon 53 skipping. Key findings include:
- Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of ...
Wave Life Sciences Announces FDA Has Granted Rare Pediatric Disease Designation To WVE-N531 For Treatment Of Duchenne Muscular Dystrophy
No comment yet